ACTINOGEN MEDICAL LTD (ACW) - Revolutionizing Mental Health Treatment: CEO Steve Gourlay on Breakthrough Xanamem Drug, Phase 2 Trial Success, and Future Implications

ASX BRIEFS

Content provided by Andrew Musgrave. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Andrew Musgrave or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

5M ago 9:45

MP3•Episode home

Send us a text

What if controlling a single hormone in your brain could revolutionize the treatment of Alzheimer's and depression? On this episode of ASX Briefs, we're joined by Steve Gourlay, CEO of Actinogen Medical, a trailblazer in biotechnology, to unveil how their groundbreaking drug, Xanamem, could be a game-changer for mental health therapies. Steve takes us through Actinogen's fascinating journey from their 2014 merger with a University of Edinburgh startup to the promising Phase 2 depression trial results, where 167 patients showed significant improvement with minimal side effects.
Steve demystifies the complex science behind Xanamem, explaining how it targets brain cortisol, a hormone infamous for its role in stress and cognitive decline. With a deep dive into the biology of the brain, Steve enlightens us on how selectively reducing cortisol in regions like the hippocampus and frontal cortex can prevent the detrimental effects of chronic stress on nerve cells. This episode is a must-listen for anyone interested in the future of mental health treatment and how innovative therapies are set to change the landscape.

104 episodes

#Trading #Business #Andrew Musgrave